Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
| Author | Hossein Saghafi | en |
| Author | Khosrow Rahbar | en |
| Author | Ali Haghighi | en |
| Author | Mohammad Qoreishi | en |
| Author | Farshad Safdari | en |
| Orcid | Hossein Saghafi [0000-0001-8338-2590] | en |
| Issued Date | 2012-03-01 | en |
| Abstract | Background: Acute rejection remains a major problem in renal transplantation and represents one of the most important causes of chronic allograft dysfunction and late graft loss. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor, and may thus reduce the risk of rejection after renal transplantation. Objectives: The aim of this study was to examine the effect of daclizumab induction therapy combined with a triple immunosuppressive protocol including prednisolone,cyclosporine microemulsion (CsA), and mycophenolate mofetil (MMF), in reducing the incidence of acute rejection in recipients of living unrelated donor kidneys. Patients and Methods: In this historical cohort study, 43 adult recipients of their first kidney allograft received daclizumab (three 1 mg/kg doses administered every 2 weeks) with triple immunosuppressive therapy (steroids, CsA, and MMF). This group was compared to 43 first-time graft recipients who received maintenance triple immunosuppressive therapy comprising steroids, CsA, and MMF. The end point was the incidence of biopsyconfirmed acute rejection within 6 months after transplantation. Results: At 6 months, 5 (11.6%) of the patients in the daclizumab group had biopsy-proven rejections, as compared to 14 (32.5%) in the control group (P = 0.017). The sex and the age of recipients had no impact on the incidence of acute rejection episodes in the two groups. Conclusions: Adding interleukin-2 receptor antibody (daclizumab) to maintenance triple immunosuppressive therapy (prednisolone, CsA, and MMF) reduces the incidence of acute rejection episodes at 6 months in first-time transplant recipients of living unrelated donor. | en |
| DOI | https://doi.org/10.5812/numonthly.1806 | en |
| Keyword | Daclizumab | en |
| Keyword | Graft Rejection | en |
| Keyword | Renal Transplantation | en |
| Publisher | Brieflands | en |
| Title | Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 16949-pdf.pdf
- Size:
- 841.04 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF